Skip to main content

Table 2 Significance testing for the group of 87 patients before neoadjuvant chemotherapy

From: Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer

Pre-chemotherapy TNM stage

GHR

n (%)

II

III

IV

p value*

≥ 45%

45

18 (40.0)

25 (55.6)

2 (4.4)

0.124

< 45%

42

23 (54.8)

19 (45.2)

0 (0.0)

 

≥ 50%

44

17 (38.6)

25 (56.8)

2 (4.5)

0.078

< 50%

43

24 (55.8)

19 (44.2)

0 (0.0)

 

≥ 2/3

30

9 (30.0)

20 (66.7)

1 (3.3)

0.021

< 2/3

57

32 (56.1)

24 (42.1)

1 (1.8)

 

≥ 90%

15

4 (26.7)

10 (66.7)

1 (6.7)

0.062

< 90%

72

37 (51.4)

34 (47.2)

1 (1.4)

 
  1. Data are presented as numbers (%).GHR graded histological regression
  2. *Mann-Whitney test